高危T1膀胱癌二次电切阴性者:主动监测对比膀胱内BCG的随机非劣效3期JCOG1019试验
JCOG1019试验纳入初次电切为高危T1、二次电切标本为T0的膀胱癌患者,随机接受主动监测或8周膀胱内BCG诱导治疗(无维持治疗)。主动监测在无浸润性复发生存方面非劣效于BCG(HR 0.69,90%CI 0.44-1.08;p=0.001),且不良事件发生率更低。
要点
- 二次电切阴性高危T1患者中,主动监测的无浸润性复发生存非劣效于8周BCG诱导治疗
- 主动监测任何级别不良事件发生率50%,BCG组90%
- 主动监测可作为经严格筛选、二次电切无残留病灶患者的潜在治疗策略
核心结论
- 在二次电切标本为T0的高危T1膀胱癌患者中,主动监测在无浸润性复发生存方面非劣效于8周膀胱内BCG诱导治疗。
- 主动监测的安全性优于BCG,可作为经严格筛选患者的潜在可行治疗策略。
研究设计与样本
- 随机非劣效3期试验JCOG1019,初次评估纳入513例,二次电切后263例随机分组。
- 干预为主动监测对比8周膀胱内BCG诱导治疗(无维持治疗),主要终点为无浸润性复发生存(iRFS)。
主要发现
- 主动监测对比BCG的iRFS风险比为0.69(90%CI 0.44-1.08;p=0.001),达到非劣效。
- 任何级别不良事件发生率:主动监测50%,BCG组90%;≥3级事件分别为3.1%和3.8%。
关键数值与推荐
- 入组条件:初次电切诊断为高危T1膀胱癌,完整切除可见肿瘤后二次电切标本为T0。
- 主要终点iRFS的HR 0.69(90%CI 0.44-1.08;p=0.001),非劣效界值未在摘要中报告。
临床怎么用
- 对于二次电切证实无残留病灶的高危T1膀胱癌患者,主动监测可作为BCG诱导治疗的替代选择。
- 选择主动监测需严格筛选患者,并与患者充分沟通复发监测与后续治疗策略。
局限性
- 对照组采用的8周BCG诱导治疗(无维持)并非当前标准方案。
- 研究人群为高度选择患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: We evaluated the noninferiority of active surveillance (AS) in comparison to intravesical bacillus Calmette-Guérin (BCG) in terms of recurrence and progression for patients with high-grade T1 (HG T1) bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB. METHODS: After initial evaluation, participants diagnosed with HG T1 bladder cancer who had undergone complete eradication of visible tumors underwent a second TURB. Those with specimens showing T0 were randomized to either AS or to intravesical BCG for 8 wk without maintenance therapy. The primary endpoint was invasive relapse-free survival (iRFS). KEY FINDINGS AND LIMITATIONS: In total, 513 participants were enrolled in the initial evaluation. After second TURB, 263 participants were enrolled and randomized. AS was noninferior to BCG in terms of iRFS (hazard ratio 0.69, 90% confidence interval 0.44-1.08; p = 0.001). Rates of adverse events were 50% and 90% for any grade, and in 3.1% and 3.8% for grade ≥3 events in the AS and BCG arms, respectively. The protocol treatment in the control arm was not the current standard. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this highly selected patient population, AS was noninferior to eight-dose intravesical BCG induction therapy in terms of iRFS for T1 disease or deeper intravesical and/or extravesical recurrence. The safety profile of AS was better than that of BCG. These findings indicate that AS represents a potentially viable therapeutic strategy for selected patients with HG T1 bladder cancer for whom second TURB demonstrates the absence of residual disease.
引用
- Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026. PMID: 41571573. doi:10.1016/j.eururo.2026.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。